Most material SEC filings — August 6, 2026

On June 15, 2026, Payoneer agreed to be acquired by Neon Maple Parent Inc. (Nuvei), a Canadian corporation, for $7.40 per share in cash, representing approximately $2.75 billion in total transaction equity value. The deal is expected to close mid-2027, subject to shareholder approval and regulatory clearance. HSR approval was granted on July 28, 2026. Upon closing, Payoneer will become private and delist from NASDAQ. The company has suspended earnings calls, financial guidance, and its share repurchase program pending transaction completion.

On July 15, 2026, LKCM Headwater Investments (already owning ~79% of DSG) agreed to acquire all remaining shares of Distribution Solutions Group at $35.00 per share in cash—an 81% premium to the March 13, 2026 closing price of $19.31 and a $5.50 increase from LKCM's initial March 14 proposal of $29.50. The transaction requires HSR approval, stockholder vote from non-LKCM shareholders, and customary closing conditions; DSG amended its credit facility to permit revolving loan financing. For Q2 2026, DSG reported revenue of $557.7M (11% YoY growth), adjusted EBITDA of $53.9M (9.7% margin), and diluted EPS of $0.18 GAAP/$0.47 non-GAAP.

On August 3, 2026, Lantheus entered into a definitive merger agreement with Curium US Holdings LLC. Curium will acquire all outstanding Lantheus shares for $102.50 per share in cash plus contingent value rights (CVRs) worth up to $12.00 per share (total consideration up to $114.50/share), representing a total transaction value of approximately $8.0 billion. The deal, unanimously approved by Lantheus's Board, creates a combined radiopharmaceutical company spanning diagnostics and therapeutics serving 70+ countries. Q2 2026 standalone results showed revenue of $388.2M (+2.7% YoY), diluted EPS of $1.11 (flat YoY), and adjusted diluted EPS of $1.55 (−1.3% YoY).

Edgewise agreed to sell its DMD/BMD drug development programs (EDG-5506/Sevasemten and backup compound) to Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55B upfront plus potential milestone payments. The transaction includes all related intellectual property, regulatory documentation, inventory, and employee transfers, with customary representations, warranties, and indemnification provisions. Closing targeted for September 30, 2026, subject to antitrust approval and other standard conditions.

The filing contains template equity award agreements (RSUs and restricted stock) that reference an "Agreement and Plan of Merger, dated as of April 13, 2026, by and between the Company, Amazon.com, Inc., Grapefruit Acquisition Sub I, Inc. and Grapefruit Acquisition Sub II, LLC." The agreements specify that vesting acceleration upon Change in Control is subject to exceptions in the Merger Agreement and Company Disclosure Letter. No dollar amounts, deal terms, or specific transaction details are disclosed in these exhibits—only boilerplate equity plan language with the merger reference embedded.

Ensysce Biosciences agreed to acquire Cy Biopharma in a two-step merger dated August 5, 2026. Merger consideration: 228,923 shares of Ensysce Convertible Preferred Stock (convertible into 228.923M shares of common stock at 1,000:1 ratio) plus 53,199 shares from convertible note conversions. Closing occurred simultaneously with signing. Company stockholders holding majority pre-approved merger via written consent and waived appraisal rights. Concurrent PIPE financing of $21.5M and convertible note financing support the transaction.

As of August 5, 2026, Eightco Holdings (market cap ~$3.8M) disclosed total holdings of approximately $378 million: $90M indirect OpenAI equity (24% of treasury), nearly 302M WLD tokens valued at ~$96M (25% of treasury, largest public WLD position at 8.4% of circulating supply), $18M Beast Industries equity, 16,278 ETH, and $142M cash/stablecoins. The company also participated in World Foundation's $52.5M funding round led by Pantera Capital.

Digital Brands Group announced receipt of an all-cash acquisition proposal on August 5, 2026 from an existing shareholder (net worth >$1B) to acquire all outstanding shares at $77.58 per share, representing a 258% premium to the then-current trading price of $21.63. The Board, assisted by retained financial advisors, will evaluate the proposal; no deadline or assurance of completion has been set. The proposal follows DBG's August 3 announcement that it had retained Roth Capital Partners to explore take-private options.

Ensysce completed acquisition of clinical-stage Cy Biopharma (developer of CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation) via stock-for-stock merger issuing 282,122 Series C Preferred shares (1:1,000 conversion ratio to common). Concurrent private placement raised $21.5M initial tranche and up to $38.6M milestone-based follow-on from Ally Bridge Group, Perceptive Advisors, Dellora, Ikarian Capital, and Adage Capital. Cy Biopharma founder James Morrison becomes President and Board member. Pro forma cash funds CY200 through Phase 2 data and into registration. Post-closing, Cy Biopharma shareholders own ~74.94%, new investors ~17.49%, and legacy Ensysce ~7.57% on fully diluted basis (equity value ~$122.9M excluding fees). Stockholder approval required for Series C conversion under Nasdaq rules.

Accuray Inc (NASDAQ: ARAY) received a notice on August 4, 2026 regarding a delisting or failure to satisfy a continued listing standard. The filing indicates a potential transfer of listing. No specific reason, dollar amounts, or remediation details are provided in this 8-K filing header.

Payoneer Global Inc. entered into a Merger Agreement dated June 12, 2026 with Neon Maple Parent Inc. (Neptune) and Panda Acquisition Sub Inc., whereby the company will be acquired and cease to be publicly traded. CEO John Caplan agreed to 75% acceleration of RSUs/PSUs at closing and 25% vesting at nine-month anniversary; 2,000,000 RSUs with stock price performance conditions are treated as fully achieved. Specific acquisition price and deal valuation are not disclosed in this excerpt.

NextCure announced a definitive all-stock merger agreement with Avere Therapeutics (July 14, 2026), expected to close H2 2026. Avere will simultaneously raise ~$320M in private financing. NextCure stockholders will receive contingent value rights (CVRs) tied to legacy assets; the combined company will trade as AVRX. NextCure halted SIM0505 enrollment, transferred LNCB74 to LigaChem as sole developer (retaining milestone/royalty rights), and took $5.1M asset impairment charge. Cash declined from $41.8M (Dec 31, 2025) to $20.1M (June 30, 2026).

CDT Equity Inc. missed three weekly installment payments ($82,125 each, totaling ~$246K) and failed to file a registration statement by July 26, 2026. Lender J.J. Astor Co. restructured the $1.97M convertible note (originally issued June 11, 2026) via Second Amendment (July 31, 2026) by: increasing principal by $377,775 Restructuring Premium to $2.27M; rescheduling 23 payments of $104,188 weekly from August 19, 2026 to January 20, 2027; raising ATM Waterfall Distribution from 80% to 90% to lender; and charging 19% Amendment Rate. Third Amendment (August 3, 2026) added $200K additional advance (factor 1.35x = $270K added principal), extending maturity to February 10, 2027, with 26 total payments. Lender reserved all default rights and imposed multiple mandatory covenants (Nasdaq listing, ATM maintenance, registration filing, share reservations).

DoubleVerify entered into a definitive merger agreement with Neptune BidCo US Inc. (Nielsen parent) on August 6, 2026 to be acquired by Nielsen Holdings. The company is suspending earnings calls and withdrawing all forward guidance for the duration of transaction pendency. No deal price, financing terms, or other material transaction details are disclosed in this filing.

On July 21, 2026, Repligen agreed to acquire BioLife Solutions for ~$1.5 billion enterprise value ($11.25 cash + 0.1442 Repligen shares per BioLife share), with closing expected Q4 2026. BioLife reported Q2 2026 revenue of $28.5M (+21% vs Q2 2025), adjusted EBITDA of $7.4M (26% margin), and adjusted net income of $4.2M (excluding $42.4M non-cash tax benefit). BioLife's biopreservation media holds ~70% market share in ~250 ongoing CGT trials and is embedded in 18 approved therapies.

Nielsen Holdings will acquire DoubleVerify Holdings for $13.60 per share in cash, representing a 30% premium to the 60-day VWAP as of August 5, 2026, and an enterprise value of approximately $2.15 billion. The all-cash transaction, unanimously approved by both boards and expected to close by end of Q4 2026, will combine Nielsen's audience measurement platform with DoubleVerify's media verification capabilities to create a ~$4 billion revenue combined entity. Providence Equity Partners, owning ~11.8% of DV shares, has committed to voting in favor; financing will come from committed debt (Barclays, BofA, Citi), incremental equity, and Nielsen's cash on hand.

Sachem Capital Corp. (market cap ~$54M) announced a pending asset contribution transaction with Industrial Realty Group (IRG), a private real estate firm. Upon closing, IRG will contribute 98 industrial properties valued at $2.9 billion to Sachem; the combined entity will operate as IRG Realty Trust, Inc. with ~$3.4 billion enterprise value, positioning it as a top-10 publicly listed industrial REIT. Q2 2026 results showed net loss of $6.5M ($0.14/share) vs. net income of $0.8M ($0.02/share) in Q2 2025, driven by $2.6M provision for credit losses and $2.6M transaction expenses. Book value per share declined from $2.46 (Dec 2025) to $2.11 (Jun 2026). IRG's leasing activity: 9.3M sq ft of new/renewal leases signed (Q2 2026–Jul 31 2026), including 4.3M sq ft new leases generating $23.1M annual base rent.

Organogenesis reported Q2 2026 net revenue of $42.8M, down 58% YoY from $100.8M, with Advanced Wound Care collapsing 61% to $36.1M and Surgical Sports Medicine declining 18% to $6.7M. Net loss widened dramatically to $96.3M (or –$0.77/share) from –$9.4M (–$0.10/share) YoY; adjusted EBITDA loss reached –$34.4M vs –$3.6M. Management cut full-year 2026 guidance to $179–$215M (62–68% decline vs 2025's $564.2M), citing slower-than-expected market recovery. Cash fell to $46.8M from $94.3M at year-end 2025; the company took $5.1M restructuring charges and terminated R&D programs totaling $5.6M.

ESAB Corporation completed acquisition of Eddyfi Holding Inc. on June 1, 2026 for approximately $1.45 billion cash consideration (subject to purchase price adjustments). Eddyfi is an industrial diagnostic technology company with $238.8M revenue (2025) and operations across North America, Europe, Latin America, and Asia. ESAB financed the deal via $1.0B senior notes (5.625% due 2031), $192M revolving credit drawdown, and $175M+$143M preferred/common stock private placements. Pro forma revenue for 2025 would be $3.08B; Q1 2026 combined revenue $802.7M.

EisnerAmper LLP consented to inclusion of their audit report (dated August 15, 2025) covering BioVie's financials for fiscal years ended June 30, 2025 and 2024 in the S-1/A filing. Critically, the auditor's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern—a red flag indicating potential insolvency risk.

Centrus Energy's subsidiary American Centrifuge Operating LLC was awarded a firm-fixed-price task order (89243226FNE400212) by the U.S. Department of Energy for $1.07 billion under an IDIQ contract. CLIN 1 is fully funded at $900 million for establishing new domestic High-Assay Low-Enriched Uranium (HALEU) capacity and delivering 1 MTU of HALEU UF6 by July 5, 2032. CLINs 2 and 3 are unfunded options worth $85 million each for 5 MTU deliveries at $17M/MTU/year. Performance period runs July 6, 2026 through July 5, 2036. Work will be performed at American Centrifuge Plant in Piketon, Ohio.

VivoSim received a $5.0M milestone payment from Eli Lilly (FXR program sale), $1.0M from escrow release, and completed a $4.0M financing (net $3.6M) via warrant issuance at $0.85/share on July 17, 2026. These post-fiscal-year-end events brought cash to $10.1M as of August 3, restored stockholders' equity above Nasdaq's $2.5M minimum, and diluted shares from 3.2M to 13.4M outstanding (9.9M new shares issued July 15–31).

Barinthus Bio announced a proposed merger with Clywedog Therapeutics expected to close in H2 2026, with the combined entity renaming to Clywedog Therapeutics Holdings and trading as CLYD. The company received a 180-day Nasdaq compliance notice on June 30, 2026, requiring it to regain the $1.00 minimum bid price by December 28, 2026, or face delisting; ADSs transferred from Nasdaq Global Market to Capital Market effective July 2, 2026. Cash declined from $67.2M (March 31) to $59.6M (June 30); Q2 net loss was $10.6M ($0.26/share) on 40.8M shares outstanding; R&D spending increased to $3.9M driven by VTP-1000 celiac disease trial, which completed enrollment of 42 subjects with topline data expected Q4 2026.

Pono Capital Four, Inc. (NASDAQ: PONO), a SPAC, has signed a definitive merger agreement with Blackstar Orbital Technologies Corporation, valuing Blackstar Orbital at $380 million. Blackstar Orbital develops SpaceDrone, a reusable orbital spacecraft platform, and has secured $1.9M in U.S. government R&D funding and $120M+ in signed commercial letters of intent. The merger is expected to close in Q1 2027, subject to Pono shareholder approval and customary closing conditions; Blackstar Orbital will become a wholly owned subsidiary and Pono will rebrand to Blackstar Orbital Corporation.

National Healthcare Corporation (buyer, operating as NHC/OP, L.P.) agreed to purchase 35 skilled nursing and assisted living facilities from National Health Investors, Inc. (seller) for $560,000,000 (base purchase price). The transaction includes a $5M initial earnest money deposit plus $15M additional deposit post-review period; seller deposits $20M as liquidated damages security. Closing targeted for July 1, 2026, contingent on HSR filing, state licensing approvals, and title insurance commitments. Separate agreement covers 5 facilities sold by National Health Corporation to NHC/OP for $50,500,000.

ALX Oncology entered a Loan and Security Agreement with HSBC Ventures USA dated June 25, 2026, for up to $50M in term loan advances ($30M Term A, $10M Term B, $10M Term C) to repay existing Oxford-SVB obligations. Draw periods are conditional on clinical milestones (ASPEN-09 Phase 2 data, ALX2004 Phase 1 safety data). Interest accrues at the greater of Prime Rate or 6.0%, with 2% prepayment premium in year 1, 1% in year 2, zero thereafter. Maturity June 1, 2030; 24-month amortization starting July 2028 (reduced to 12 months if milestone achieved). Security interest granted over all assets; guarantees from Parent (ALX Oncology Holdings) and Irish subsidiary.

Artiva Biotherapeutics completed a ~$300M underwritten offering in May 2026, bringing cash/equivalents/investments to $349.4M (expected to fund operations into 2029). The company received FDA RMAT designation for AlloNK plus rituximab in refractory RA and announced initiation of a Phase 3 randomized controlled trial (~150 patients, H2 2026) comparing AlloNK+rituximab vs. rituximab alone. Phase 2a data showed 71% (5/7) ACR50 response rate in refractory RA; no serious adverse events or treatment discontinuations observed among 55 safety-evaluable patients.

On April 26, 2026, RE/MAX Holdings agreed to be acquired by The Real Brokerage Inc. in an all-stock and cash merger. RE/MAX shareholders may elect 5.15 shares of the combined entity or $13.80 cash per share (aggregate cash $60M–$80M); deal expected to close H2 2026 pending shareholder votes scheduled for August 14, 2026. Q2 2026 revenue fell to $68.5M (down 5.8% YoY); net loss was $4.3M; adjusted EBITDA declined 12.6% to $22.9M with margin compression from fee model changes and US agent attrition. Company suspended guidance and quarterly calls pending merger completion.

Roku delivered Q2 2026 results with Platform revenue of $1.22B (up 25% YoY), net income of $164M, Adjusted EBITDA of $254M, and Free Cash Flow (TTM) of $704M—all record highs. Advertising revenue grew 25% YoY to $673M with 62.4% gross margin; Subscriptions grew 26% YoY to $548M. On June 15, 2026, Fox Corporation announced a definitive agreement to acquire Roku; the company will not host an earnings call or provide forward guidance pending transaction close.

On April 27, 2026, BioMarin Pharmaceutical Inc. completed its merger with Amicus Therapeutics, Inc., with Amicus becoming a wholly owned subsidiary of BioMarin. The Amicus 2025 Equity Incentive Plan was assumed by BioMarin effective April 27, 2026, covering 4,355,297 shares of common stock available for issuance under the assumed plan. BioMarin's own 2017 Equity Incentive Plan remains in effect with a total share reserve of 72,030,015 shares.

Braemar Hotels & Resorts agreed to sell three properties—Bardessono Hotel & Spa (Yountville, CA), Hotel Yountville (Yountville, CA), and Ritz Carlton Sarasota (Sarasota, FL)—to four purchaser entities for a total purchase price of $437,500,000. The agreement, dated June 4, 2026, with an initial closing date of July 1, 2026, includes a $8,750,000 deposit ($5,550,000 pre-signed, $3,200,000 additional). The transaction involves multiple contingencies including consents from the Bardessono Ground Lessor and Town of Yountville regarding the Workforce Housing Agreement, with acquisition financing of $295,100,000 required from Purchaser's lender.

AIM ImmunoTech engaged Sterling Pharma Solutions for development, analytical validation, and cGMP manufacture of two polynucleotide drug substances—PolyI and Poly C12U—under a proposal dated July 24, 2026, valued at $1,446,200. The work includes process development (12 weeks), non-GMP demonstration batches (3 weeks each), analytical method validation, capital equipment expenditure, and one cGMP batch each of PolyI and Poly C12U solution. Proposal signed by both parties on July 31, 2026; major cost components redacted.

CEO and Interim CFO Lim Jung Jae (REBN) bought 131K shares (~$23.6B) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

FDA granted accelerated approval on August 6, 2026 for TUDRIQEV (vusolimogene oderparepvec-wtpg) combined with nivolumab for unresectable advanced cutaneous melanoma progressing after anti-PD-1 therapy. In the IGNYTE trial (n=91 efficacy-evaluable), the combination achieved 24.2% objective response rate with 14.1-month median duration of response; adverse events were predominantly grade 1–2. Approval is conditioned on confirmatory Phase 3 IGNYTE-3 trial completion. Company targets ~10,000 addressable U.S. patients and plans commercial launch with manufacturing facility to ship product within ~60 days.

Oscar Health reported H1 2026 net income of $1.04B ($3.16 diluted EPS) versus $47M ($0.17) in H1 2025, on revenue of $9.53B versus $5.91B. The company raised full-year 2026 operating earnings guidance from $250–450M to $500–700M, improved MLR from 83.0% to 75.0% (H1 YoY), and maintained revenue guidance of $18.7–19.0B. Membership grew to 2.96M (Individual/Small Group) from 2.02M YoY. CEO cited disciplined pricing, improved underwriting, and $164M favorable prior-period reserve development.

Teads reported Q2 2026 revenue of $284.6M (down 17% YoY from $343.1M), with net loss of $42.5M versus $14.3M loss in Q2 2025. Adjusted EBITDA fell 74% to $7.0M. The company suspended full-year 2026 guidance, citing volatility in Direct Response and SME business, though CTV revenue grew 67% YoY. Cash position declined to $88.0M from $128.2M at year-end 2025; total debt stands at $614.5M ($607.4M in 10% senior secured notes due 2030).

Leggett & Platt reported Q2 2026 sales of $1.0B (down 6% YoY), with adjusted EPS of $0.39 (up $0.09 vs Q2 2025). The company is pending completion of its acquisition by Somnigroup International Inc., with HSR approval obtained in June and shareholder vote scheduled for August 20, 2026. Adjusted EBIT was $89M (up from $76M), driven by metal margin expansion and restructuring benefits, though management notes these favorable items are not expected to repeat. Debt stands at $1.5B with net leverage at 2.6x trailing adjusted EBITDA.

Sunrise Realty Trust, Inc. (SUNS, ~$105.5M market cap) has agreed to merge with Southern Realty Trust Inc. (SRT) in a stock-for-stock transaction. SRT shareholders will receive 1.45 SUNS shares per SRT share, plus $0.05 per share in cash from SUNS Manager. The merger is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. Both companies are Maryland REITs; SRT shareholders must approve the merger, SUNS shareholders must approve the stock issuance. Closing expected within ~3 business days of condition satisfaction.

On August 2, 2026, TripAdvisor entered an Equity Purchase Agreement to sell TheFork (its European restaurant platform) to American Express Travel Related Services for $700.0 million in cash, subject to adjustments. The transaction was exercised via put option on August 1, 2026, following French Works Council consultation. Closing is expected by end of 2026, subject to regulatory approvals. TheFork's results are now classified as discontinued operations.

Avalo reported Q2 2026 results with cash/investments of $472.2M (8.8x market cap), providing runway into 2029. The company plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027 following positive Phase 2 LOTUS results. Pipeline expanded with AVTX-010, a long-acting anti-IL-1β antibody with IND submission planned for H1 2027. Q2 net loss was $36.4M; operating cash burn was $37.7M for six months.

Nexstar closed its $3.657B TEGNA acquisition on March 19, 2026 (funded in H1 2026), generating record Q2 net revenue of $1.993B (+62.2% YoY, including $697M from TEGNA) and Adjusted EBITDA of $633M. However, DIRECTV and state attorneys general sued challenging the deal under antitrust law; the U.S. District Court (E.D. California) issued a preliminary injunction on April 17, 2026 requiring the entities be held separate pending trial scheduled for July 6, 2027. The D.C. Circuit rejected regulatory challenges on July 9, 2026. Total debt rose to $11.744B (from $6.333B at Dec 31, 2025); pro forma first lien net leverage is 3.21x vs. 4.75x covenant, and total net leverage is 4.22x. The company repaid $409M debt and paid $57M in dividends in Q2 2026.

Unity reported Q2 2026 total revenue of $546.5M (up 24% YoY), with strategic revenue of $486.4M (up 38% YoY), driven primarily by Grow Solutions revenue of $389M (up 35%), powered by Vector AI platform. The company swung to near break-even with GAAP net loss of $23M (down from $107M loss YoY) and adjusted EBITDA of $160M at 29% margin. Management divested Supersonic game publishing business on August 4, 2026, and sunset ironSource Ads Network; Q3 guidance projects strategic revenue of $540-550M (up 44-47% YoY) and adjusted EBITDA of $185-190M (up 69-74% YoY). Cash position strengthened to $2.36B.

Viridian received FDA approval for Lumvoa (veligrotug-vvze) for thyroid eye disease on June 26, 2026, launched immediately with 95% physician engagement as of July 31. The company completed a $394M convertible debt and equity financing in May 2026, bringing cash to $981.5M as of June 30, 2026. Elegrobart is on track for BLA submission Q1 2027, and TSHR program IND submission is expected Q4 2026.

Vital Farms reported Q2 2026 net revenue of $166.0M (down 10.1% YoY) with a net loss of $31.1M versus prior-year net income of $16.6M, driven by industry-wide egg oversupply and $19.5M in excess breaker sales at depressed prices. Gross margin collapsed to 6.6% from 38.9% YoY. The company closed new credit facilities: a $125M 3-year term loan and a $60M 3-year asset-based lending facility, replacing prior revolving credit. On August 3, 2026, the Board terminated the stock repurchase program (1.1M shares at $13.29/share had been repurchased for $15.0M in Q2). Cash declined to $21.2M from $48.8M at year-end 2025. Full-year FY2026 guidance maintained: $775M–$800M revenue and $0M–$10M Adjusted EBITDA, assuming oversupply costs of mid-$30M range.

Iovance reported Q2 2026 product revenue of $99.3M (vs. $59.9M in Q2 2025), driven by U.S. Amtagvi sales of ~$91M (+40% vs. Q4 2025) and Proleukin revenue of ~$9M. Gross margin improved to 56%. The company is reviewing its FY2026 revenue guidance ($350M–$370M) based on strong demand and will update in Q3. FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma). Amtagvi now approved in three markets (U.S., Australia, Canada); UK resubmission under expedited review. Cash position was $304M as of June 30, 2026, expected to fund operations into H2 2028. Net loss for H1 2026 was $126.4M on revenue of $170.7M.

Resolute Holdings reported Q2 2026 results following its January 2026 execution of a management agreement with Husky Holdings LLC. Management fees grew to $13.6M (Q2 2026) from $3.4M (Q2 2025); Non-GAAP Fee-Related Earnings per share rose to $0.69 from $0.08 year-over-year. The company repurchased $50.0M in common shares since the spin-off, reducing shares outstanding by approximately 8.3% (from 8.5M to 7.8M shares as of June 30, 2026). GAAP net loss attributable to common stockholders was $(12.4)M in Q2 2026 due to a $18.0M tax consolidation impact, though six-month GAAP net income was $49.1M. Long-term debt increased to $2,153.5M (net) from $169.1M at year-end 2025, reflecting financing of the Husky acquisition.

Vistance Networks' Board approved a special cash distribution of $5.00 per share payable August 27, 2026, to shareholders of record as of August 17, 2026. The distribution is funded by proceeds from the July 1, 2026 sale of Ruckus Networks business to Belden Inc. Since the $5/share represents ≥25% of stock value, the ex-dividend date is August 28, 2026 (first business day after payment).

On July 1, 2026, Vistance completed the sale of its RUCKUS segment to Belden Inc. for approximately $1.846 billion in cash. The company announced a $5.00 per share special distribution to be paid by end of August 2026. Combined with prior distributions, shareholders will receive $15.00 per share in total distributions for 2026; the company repaid all debt and redeemed all preferred equity. Post-distribution, Vistance expects $700–$750 million cash with no debt by year-end and anticipates a $160 million tax refund in 2027.

Scholar Rock reported Q2 2026 results with net loss of $109.9M (vs. $110.0M YoY), no revenue, and cash of $492.1M (up $124.5M from Dec 2025, including $62.8M from ATM offering). The lead candidate apitegromab for spinal muscular atrophy (SMA) has an FDA BLA with two independent fill-finish facility pathways toward potential approval by Sept 30, 2026 PDUFA date; a Phase 2 FORGE trial in FSHD initiated; and Phase 1 SRK-439 ongoing with topline data expected late 2026.

Precision BioSciences reported Q2 2026 results with clinical milestone data from PBGENE-HBV showing first-ever biopsy proof of direct cccDNA elimination (1-log reduction in one patient, <1% remaining after 2 doses at 0.4 mg/kg) and sustained pgRNA loss in 100% of evaluable patients. The company has $112.4M in cash as of June 30, 2026, expected to fund operations through 2028. Q2 net loss was $32.7M ($1.26/share); G&A costs decreased $2.3M YoY but warrant liability fair-value adjustments increased $13.5M non-cash loss YoY.